https://www.elsevier.es/en-revista-neurologia-english-edition--495-articulo-early-beginning-alemtuzumab-changing-multiple-S2173580823000159
IntroductionLEMVIDA is a real-world prospective study of 3-year follow-up on quality of life of
multiple sclerosisearlybeginningalemtuzumabchanging
https://www.mdpi.com/2077-0383/12/5/1768
Background and objectives: alemtuzumab is a monoclonal anti-CD52 antibody acting on B and T cells in highly active multiple sclerosis (MS).
alemtuzumabrelatedlymphocytesubsetdynamics